Peroxisome proliferator-activated receptor ligands in atherosclerosis

Juan F. Viles-Gonzalez; Brian G. Choi; Valentin Fuster; Juan J. Badimon

doi:10.1517/13543784.13.11.1393

Peroxisome proliferator-activated receptor ligands in atherosclerosis

Juan F. Viles-Gonzalez, Brian G. Choi, Valentin Fuster, Juan J. Badimon

Medicine

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.

Original language	English (US)
Pages (from-to)	1393-1403
Number of pages	11
Journal	Expert Opinion on Investigational Drugs
Volume	13
Issue number	11
DOIs	https://doi.org/10.1517/13543784.13.11.1393
State	Published - Nov 1 2004

Keywords

Atherosclerosis
Coronary artery disease
Fibrate
PPAR
Thiazolidinedione

ASJC Scopus subject areas

Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1517/13543784.13.11.1393

Cite this

@article{379dcdea1c9249e5b2397ca43b69b201,

title = "Peroxisome proliferator-activated receptor ligands in atherosclerosis",

abstract = "In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.",

keywords = "Atherosclerosis, Coronary artery disease, Fibrate, PPAR, Thiazolidinedione",

author = "Viles-Gonzalez, {Juan F.} and Choi, {Brian G.} and Valentin Fuster and Badimon, {Juan J.}",

year = "2004",

month = nov,

day = "1",

doi = "10.1517/13543784.13.11.1393",

language = "English (US)",

volume = "13",

pages = "1393--1403",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor ligands in atherosclerosis

AU - Viles-Gonzalez, Juan F.

AU - Choi, Brian G.

AU - Fuster, Valentin

AU - Badimon, Juan J.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.

AB - In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.

KW - Atherosclerosis

KW - Coronary artery disease

KW - Fibrate

KW - PPAR

KW - Thiazolidinedione

UR - http://www.scopus.com/inward/record.url?scp=8844274788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844274788&partnerID=8YFLogxK

U2 - 10.1517/13543784.13.11.1393

DO - 10.1517/13543784.13.11.1393

M3 - Review article

C2 - 15500388

AN - SCOPUS:8844274788

VL - 13

SP - 1393

EP - 1403

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 11

ER -

Peroxisome proliferator-activated receptor ligands in atherosclerosis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this